"Including evidence-based decision-making in the healthcare coverage process would ensure that use of new therapy and technology is tied to evidence of clinical benefit, resulting in a value-based health care system."

Rita Redberg, MD.
Health Affairs, February 2007

QUICK LINKS

» About
» Databases
   
Stanford LoginPubMed 
   
 Stanford Login UpToDate
   
Stanford Login MD Consult
   
Stanford Login Web of Science
   
Stanford Login Ovid 
   More
» Links
» Newsletter
» Partners
» Portfolio
» Presentations
» Publications
»
Staff



275 Middlefield Road
Suite 200

Menlo Park, CA 94025

Tel: 650.327.2085
Toll-free: 877.571.3779
Fax: 650.327.1506
Email: info@cedarecon.com
Cedar Associates LLC provides life sciences organizations and companies with scientifically reliable and credible evidence on clinical outcomes and economics of services and technologies. We use state-of-the-art analytical techniques and seek to present our findings in a manner that is readily understood by a diverse audience, such as physicians, patients, managers, and third-party payers and decision-makers.

We have close collaborations with numerous international renowned experts at local, regional and national institutions (e.g., Stanford University, UC Berkeley, California State University East Bay, Sutter Health, Veterans’ Affairs Hospitals). These collaborations not only expand the scope of state-of-the-art expertise on projects, but increase our capacity to readily staff projects.

Cost Effectiveness

We provide state-of-the-art analyses of the economic implications of medical technologies (pharmaceuticals, devices, and diagnostics) and services. Based on a strong foundation in decision analyses, epidemiology, statistics, and econometricscombined with more than a decade of experience working in and with life sciences companieswe generate analyses that are useful for a diverse array of stakeholders.

Budget Impact

Third-party payers routinely need and request high-quality evidence on the potential fiscal implications of funding new and emerging health technologies and services. We believe that such discussions should be based on the foundation of "principled negotiations." Analyses to inform these discussions require a mutual understanding and agreement on diverse set of inputs. We have extensive experience obtaining reliable information to such question and developing credible fiscal forecasts.

Strategy

Cedar Associates LLC assists company decision makersfrom regulatory, clinical, commercial, and reimbursement teamsto develop an effective strategy for commercializing a new product. Our emphasis is primarily on the economic and reimbursement strategy, and our experience reveals that it must be informed from input of other teams.

Evidence Synthesis

We conduct systematic reviews of medical literature according to the standards expected from major stakeholders. Our staff retrieves pertinent publications and abstracts from international congresses. We also rely on clinical and economic experts to fill in potential gaps from using electronic databases. We generate evidence reports that have been submitted for use in AMCP dossiers and NICE submissions, and for reports to regulatory agencies, clinical investigators, and senior managers.

Statistics and Econometric Analysis

Our staff has experience programming in SAS, STATA, S-Plus, Mathematica, and R-statistical language. Our analyses have been published in peer-reviewed journals, submitted to FDA, and submitted to reimbursement agencies (CMS, UK NICE). We have experience with survival models, ANOVA models, multivariate regression (Cox, GLM, GEE, fixed and random effect models, logistic), time series, and Bayesian methods and forecasting. 
2010 INFORMATION SESSION

Cedar Associates will be holding an information session on March 5, 2010. The session will consist of familiarizing attendees with decision analysis, biotech and pharmaceutical consulting, and specific career opportunities at Cedar.

Additional time will be allotted for fielding queries about the role of the RESEARCH ANALYST. All attendees are welcome to sign up for OCR interviews at their respective schools taking place in March.

Attire: Business Casual

Relevant Majors: Life sciences, Public Health, Economics/Business Administration

OPEN TO ALL STUDENTS, ALL GRADES

RSVP by 3/3 to info@cedarecon.com

If interested but cannot attend, please email info@cedarecon.com or call 650.327.2085, ext 112  

PRESS RELEASES

November 3, 2009   A manuscript titled “Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli managed healthcare organization,” co-authored by John Hornberger, MD, MS and Julie Doberne with Shmuel Klang, PhD has been accepted by Value In Health for publication. Read more.

September 14, 
2009   Economic evaluation of R-CVP, written by Dr. Hornberger in collaboration with Carolina Reyes (Genentech Inc.), Deborah Lubeck (ICON Clinical Research), and Nancy Valente (Genentech Inc.), favorably reviewed by the NHS Centre for Reviews and Dissemination (CRD). Read more.

June 26, 
2009   Policy analysis by John Hornberger, MD, MS, on American health care reform was featured in the May/June 2009 issue of ISPOR connections. Read more.

May 5, 2009
  Molecular Diagnostics cites Cedar Associate LLC's economic analysis of Genomic Health's Oncotype DX as a "gold standard in novel diagnostics economic analysis." Read more.

April 23, 2009  
JIAPAC publishes Cedar manuscript coauthored by Ashwini Shewade, MS, John Hornberger, MD, MS, and John Bartlett, MD, which proposes practical solutions to barriers to antiretroviral treatment in resource-limited settings. Read more.

April 10, 2009   John Hornberger, MD, MS, founder of Cedar, will be presenting a session on Pharmaeconomics, Cost Effectiveness, and Outcome Analysis for Personalized Medicine at the Drug Information Association's 45th Annual Meeting. Read more.

February 18, 2009   Poster coauthored by Cedar Associates Research Analyst, Julie Doberne, on capsule endoscopy was accepted for presentation at Digestive Disease Week. Read more.

February 9, 2009   Cedar presents report to Government Accounting Office (GAO) on the financial implications of home hemodialysis. Read more.

© 2009 Cedar Associates LLC  |  About Us  |  Contact  |  Terms of Use  |  Site Map